1,174 reports of this reaction
4.6% of all BIMEKIZUMAB reports
#4 most reported adverse reaction
PSORIATIC ARTHROPATHY is the #4 most commonly reported adverse reaction for BIMEKIZUMAB, manufactured by UCB, Inc.. There are 1,174 FDA adverse event reports linking BIMEKIZUMAB to PSORIATIC ARTHROPATHY. This represents approximately 4.6% of all 25,281 adverse event reports for this drug.
Patients taking BIMEKIZUMAB who experience psoriatic arthropathy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIATIC ARTHROPATHY is moderately reported among BIMEKIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to psoriatic arthropathy, the following adverse reactions have been reported for BIMEKIZUMAB:
The following drugs have also been linked to psoriatic arthropathy in FDA adverse event reports:
PSORIATIC ARTHROPATHY has been reported as an adverse event in 1,174 FDA reports for BIMEKIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIATIC ARTHROPATHY accounts for approximately 4.6% of all adverse event reports for BIMEKIZUMAB, making it a notable side effect.
If you experience psoriatic arthropathy while taking BIMEKIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.